Research and Markets: Injectable Generic Drugs: Prospects & Opportunities to 2013
2008-07-25 05:22:00
Research and Markets: Injectable Generic Drugs: Prospects & Opportunities to 2013
DUBLIN, Ireland–(EMWNews)–Research and Markets (http://www.researchandmarkets.com/research/9d0b85/injectable_generic)
has announced the addition of the “Injectable Generic Drugs: Prospects &
Opportunities to 2013” report to their offering.
This report provides:
-
Individual analysis of 48 leading therapies
-
Product forecasts by value 2008/2013
-
Comprehensive patent information by product and patent expiry
opportunities to 2015
-
The market context for injectable drugs
-
Evaluation of companies competing in the sector
-
Analysis of significant litigation
Key therapy sectors covered:
-
Cancer
-
CNS
-
Cardiovascular
-
Anti-Infectives
-
Diabetes
-
Growth Disorders
Some of the most promising generic drug opportunities due to come off
patent in the USA and Europe over the next few years are injectable.
This new report focuses on the market potential for sterile drugs
delivered by injection or infusion. These drugs are used to treat major
illnesses, such as cancer, central nervous system (CNS) disorders, acute
cardiovascular conditions and severe infections. More than one third of
the injectable generics approved in the US during the last five years
are used in cancer therapy. A further 23% are anti-infectives, 16% are
used in the CNS setting and 9% are used for cardiovascular therapy.
A relatively small number of injectable drugs have received significant
attention from generic companies, resulting in the approval of numerous
versions following patent expiry. Some of these are high profile cancer
drugs. For example, when Bristol-Myers Squibb’s
Paraplatin (carboplatin) became generically available 11 companies
received FDA approval for generic versions.
Key Topics Covered:
Foreword
Executive Summary
Overview
Leading Generic Markets
Injectables
Major Therapeutic Areas
Leading Companies and Competition
EMEA Guidelines for Recombinant Granulocyte-Colony Stimulating Factor
Recombinant Human Growth Hormone
Appendix I: FDA ANDA Approvals
Appendix II: UK Injectable Generic Approvals
SOURCES
Companies Mentioned:
-
Amphastar Pharmaceuticals
-
Apotex
-
APP Pharmaceuticals
-
Baxter Healthcare
-
Bedford Laboratories
-
Hikma Pharmaceuticals
-
Hospira
-
Orchid Healthcare
-
Paddock Laboratories
-
PharmaForce
-
Sagent Pharmaceuticals
-
Sandoz
-
Sun Pharma
-
Teva Pharmaceutical Industries
-
Wockhardt
For more information visit http://www.researchandmarkets.com/research/9d0b85/injectable_generic.
Source: Espicom Business Intelligence Ltd
Research and Markets from USA: 646-607-1907 |
|
Major Newsire & Press Release Distribution with Basic Starting at only $19 and Complete OTCBB / Financial Distribution only $89
Get Unlimited Organic Website Traffic to your Website
TheNFG.com now offers Organic Lead Generation & Traffic Solutions